Figure 3
IL-23 and PD-1 mAb synergistically enhance the cytotoxic effect of TNBC cell-specific CTLs in vivo. (A) Illustration of the animal study. When the tumor reached approximately 30 mm3, PBS control (n = 3–5) or MDA-MB-231-specific CTLs (n = 12–20) were intravenously administrated into the tail vein. Next, mice received administration of CTLs were intravenously treated with PBS control, IL-23, PD-1 mAb, and a combination of IL-23 and PD-1 mAb (n = 3–5 in each group), respectively. The treatment was performed once a week for a total of 2 treatments. Tumor size was measured every two days with a caliper. (B) Tumor growth curves of the xenograft tumors. Photographs of tumors from the four groups that received CTLs administration were exhibited. The mice that received only PBS treatment were sacrificed when the difference in tumor volume was significant compared to the other four groups. (C) The representative immunofluorescence staining of CK-pan, CD8, Granzyme B, and Ki67 in the xenograft tumors from mice that received CTLs treatment. Scale bars 100 μm. (D) The quantifications of infiltration of CD8+ T cells, Ki-67 positive cells, and the fluorescence intensity of Granzyme B in the xenograft tumors from mice that received CTLs treatment. Error bars represent SD, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
